FY2018 EPS Estimates for Novartis AG Decreased by Jefferies Group (NVS)
Novartis AG (NYSE:NVS) – Investment analysts at Jefferies Group cut their FY2018 earnings per share estimates for Novartis AG in a research report issued on Wednesday. Jefferies Group analyst J. Holford now expects that the company will post earnings of $5.29 per share for the year, down from their previous estimate of $5.32. Jefferies Group also issued estimates for Novartis AG’s FY2019 earnings at $5.94 EPS.
Novartis AG (NYSE:NVS) last issued its earnings results on Tuesday, July 18th. The company reported $1.22 EPS for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.06. Novartis AG had a net margin of 13.52% and a return on equity of 15.51%. The business had revenue of $12.24 billion for the quarter, compared to the consensus estimate of $12.20 billion. During the same quarter last year, the firm posted $1.23 EPS. The business’s revenue for the quarter was down 1.8% compared to the same quarter last year. ILLEGAL ACTIVITY WARNING: “FY2018 EPS Estimates for Novartis AG Decreased by Jefferies Group (NVS)” was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/06/fy2018-eps-estimates-for-novartis-ag-decreased-by-jefferies-group-nvs.html.
Other equities analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of Novartis AG from a “hold” rating to a “buy” rating and set a $96.00 target price for the company in a research note on Tuesday, September 19th. Leerink Swann reiterated a “market perform” rating and set a $83.00 target price on shares of Novartis AG in a research note on Thursday, June 22nd. Morgan Stanley upgraded shares of Novartis AG from an “underweight” rating to an “overweight” rating in a research note on Wednesday, July 26th. Credit Suisse Group AG cut shares of Novartis AG from a “neutral” rating to an “underperform” rating and set a $82.25 target price for the company. in a research note on Wednesday, July 5th. Finally, Cowen and Company set a $77.00 target price on shares of Novartis AG and gave the company a “hold” rating in a research note on Tuesday, July 11th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $85.12.
Novartis AG (NYSE:NVS) traded up 0.12% during midday trading on Friday, reaching $85.74. 489,627 shares of the company traded hands. Novartis AG has a 12 month low of $66.93 and a 12 month high of $86.90. The stock has a market capitalization of $200.88 billion, a price-to-earnings ratio of 31.30 and a beta of 0.73. The firm has a 50 day moving average of $84.76 and a 200-day moving average of $81.32.
Institutional investors have recently made changes to their positions in the stock. City Holding Co. grew its holdings in Novartis AG by 4.6% during the 2nd quarter. City Holding Co. now owns 1,217 shares of the company’s stock worth $102,000 after acquiring an additional 54 shares during the last quarter. WFG Advisors LP grew its holdings in Novartis AG by 38.1% during the 2nd quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock worth $102,000 after acquiring an additional 337 shares during the last quarter. Archford Capital Strategies LLC grew its holdings in Novartis AG by 72.3% during the 1st quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock worth $110,000 after acquiring an additional 621 shares during the last quarter. Kernodle & Katon Asset Management Group LLC grew its holdings in Novartis AG by 3.4% during the 1st quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock worth $111,000 after acquiring an additional 49 shares during the last quarter. Finally, Massey Quick & Co. LLC bought a new stake in Novartis AG during the 1st quarter worth about $119,000. Institutional investors and hedge funds own 10.93% of the company’s stock.
About Novartis AG
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.